LALisha Ai

Lisha Ai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisha Ai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Peng

    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    4 shared publications
  • Jingwen Li

    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    4 shared publications
  • Shidai Mu

    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    4 shared publications
  • You Qin

    Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    4 shared publications
  • Yu Hu

    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Chunyan Sun

    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    1 shared publication

Latest Publications

  • Open Access

    Epidemiological features for primary lymphoma of the female genital tract patients and development of a nomogram to predict survival

    by Fei Peng, Jingwen Li, Shidai Mu, You Qin, Jiewen Ma, Lisha Ai, Yu Hu

    Primary lymphoma of the female genital tract (PLFGT) is a sporadic extranodal lymphoma. Its epidemiology and prognosis are not fully recognized. Our study aimed to construct and validate prognostic...


  • Open Access

    Epidemiological Features for Primary Lymphoma of the Female Genital Tract Patients and Development of a Nomogram to Predict Survival

    by Fei Peng, Jingwen Li, Shidai Mu, You Qin, Lisha Ai, Yu Hu

    Background: Primary lymphoma of the female genital tract (PLFGT) is a sporadic extranodal lymphoma. Its epidemiology and prognosis are not fully recognised. Our study aimed to construct and validate prognostic nomograms for predicting survival for patients with PLFGT.Methods: Incidence rate from 1975 to 2017 and patients with PLFGT from 1975 to 2011 in the Surveillance, Epidemiology and End Results (SEER) database were retrospectively reviewed. The nomograms of OS and DSS were established according to the multivariate Cox regression analyses. The concordance index (C-index) and calibration plots were used to demonstrate its robustness and accuracy.Results: A total of 617 PLFGT patients were identified. The overall incidence of PLFGT is 0.44/1,000,000 (adjusted to the US standard population in 2000) from 1975 to 2017. Age, histological subtype, Ann Arbor Stage, and therapeutic strategy were identified as independent prognostic factors for overall survival (OS) and disease-specific survival (DSS) by multivariate Cox regression (P < 0.05). Nomograms to predict 1-, 5-, and 10- year OS and DSS were established. The C-index and calibration plots showed a good discriminative ability and an optimal accuracy of the nomograms. Patients were devided into three risk groups according to the model of OS.Conclusions: The nomograms were developed and validated as an individualized tool to predict OS and DSS.

  • Open Access

    Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival

    by Fei Peng, Jingwen Li, Shidai Mu, Li Cai, Fengjuan Fan, You Qin, Lisha Ai, Yu Hu


  • Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis

    by Fei Peng, You Qin, Shidai Mu, Jingwen Li, Lisha Ai, Yu Hu

    Purpose The regulatory T cells (Tregs) are a subpopulation of lymphocytes that suppress the immune responses. The prognostic value of Tregs in lymphoma patients remains controversial. Thus, we conducted this meta-analysis to clarify the role of Tregs in the prognosis of lymphoma patients. Methods We searched PubMed, Embase, and Web of Science to obtain eligible studies that evaluated the prognostic factor of Tregs for lymphoma patients. Hazards ratios (HRs) with the matching 95% confidence intervals (95%CIs) were merged to estimate the prognostic value of Tregs. Results We finally retrieved 23 eligible studies, including a total of 2269 patients. The overall pooled analysis on all types of lymphomas showed that Tregs had a significantly positive association with prolonged overall survival (OS) (HR = 0.633, 95% CI 0.528–0.758) and progression-free survival (PFS) (HR = 0.451, 95% CI 0.261–0.779). Subgroup analysis indicated that high Tregs were significantly correlated with longer OS in Hodgkin lymphoma, diffuse large B cell lymphoma, and natural killer/T cell lymphoma. However, there was no significant association of Tregs with T cell lymphoma and follicular lymphoma. Conclusions Increased Tregs indicates a better prognosis for patients with lymphoma. Tregs could be used as a valuable prognostic biomarker of lymphoma patients.


  • Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis

    by Li Cai, Xiaoyan Zhao, Lisha Ai, Huafang Wang

    Hypomethylating agents (HMAs) are now a major treatment option for myelodysplastic syndrome (MDS) and related neoplasms, but 50% of patients still do not respond and realize poor outcomes. Mutational predictors of treatment efficacy attract continuous attention. Whether TP53 mutations can be used as predictors of HMA effectiveness has caused heated debate. Therefore, we performed a meta-analysis to investigate the predictive value of TP53 mutations to outcomes of HMA therapy in patients with MDS and related neoplasms. We systematically searched PubMed, Embase, the Cochrane Library, and the WanFang databases (published deadline: September 12, 2019). The primary endpoints were overall response rate (ORR) and overall survival (OS). Odds ratio (OR), hazard ratio (HR), and 95% confidence intervals (CI) were pooled to estimate the association between TP53 mutations and the clinical efficacy of HMAs. Four hundred fifteen papers were found, and 22 papers were included in this meta-analysis (N = 2020 participants). The results showed that the presence of TP53 mutation predicted an increased overall response rate with HMA treatment in the subsets that restricted patients in de novo disease, MDS by WHO (World Health Organization) criteria, or NGS (next-generation sequence) group (P = 0.005,P = 0.003,P = 0.0005, respectively). However, TP53 mutations remained poor factors for OS (P < 0.00001). Collectively, in HMA therapy, TP53 mutations can predict better ORR when setting more refined subgroups, but TP53 mutations still strongly correlated with poor survival in hypomethylating therapy.


  • Open Access

    Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis

    by Shidai Mu, Lisha Ai, Fengjuan Fan, Chunyan Sun, Yu Hu

    Recent studies have emphasized the important prognostic role of long noncoding RNAs (lncRNAs) in various types of cancers. Here we conducted a meta-analysis to investigate whether lncRNA HOXA11-AS can be served as a prognostic biomarker in human cancers. We systematically searched PubMed, Embase, ISI Web of Science, and SCOPUS for relevant studies, to investigate the prognostic significance of HOXA11-AS expression in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between HOXA11-AS expression and clinicopathological parameters or survival of cancer patients. A total of eight eligible studies with 1320 cancer patients were enrolled in our meta-analysis. The results revealed that increased expression level of HOXA11-AS was significantly associated with clinicopathological parameters including more lymph node metastasis (OR = 2.06, 95% CI 1.31–3.25), advanced tumor stage (OR = 4.22, 95% CI 2.60–6.85), as well as poor tumor differentiation (OR = 2.49, 95 CI 1.47–4.20), but not correlated with age (p = 0.101) or gender (p = 0.845). In addition, cancer patients with high HOXA11-AS are prognosed to have shorter OS (pooled HR = 1.86, 95% CI 1.39–2.48) and PFS (pooled HR = 2.47, 95% CI 1.29–4.75). HOXA11-AS overexpression might be a convinced unfavorable prognostic factor that helps the clinical decision-making process.